Pamela Esposito, Director at Kymera Therapeutics, Inc. (KYMR), sold 5,000 shares at $77.71 ($396K) on 2026-03-20, disclosed to the SEC on 2026-03-20.
Scheduled sale ($396k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $77.71 | 700 | $54K | 13.7% |
| 2 | $77.71 | 700 | $54K | 13.7% |
| 3 | $79.24 | 600 | $48K | 12.0% |
| 4 | $79.24 | 600 | $48K | 12.0% |
| 5 | $79.94 | 1,200 | $96K | 24.2% |
| 6 | $79.94 | 1,200 |
| $96K |
| 24.2% |
| Total | $79.15 avg | 5,000 | $396K | 100% |
| Filing → |
| KYMR | SELL | 2025-12-17 | $4.4M | — | Filing → |
| KYMR | SELL | 2025-06-03 | $245K | — | Filing → |
| KYMR | SELL | 2024-12-02 | $123K | — | Filing → |